Edition:
United States

OncoTherapy Science Inc (4564.T)

4564.T on Tokyo Stock Exchange

249JPY
26 Sep 2017
Change (% chg)

-- (--)
Prev Close
¥249
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
1,333,644
52-wk High
¥338
52-wk Low
¥221

Latest Key Developments (Source: Significant Developments)

OncoTherapy Science says close of peptide vaccine related agreement with ONO PHARMACEUTICAL
Tuesday, 1 Aug 2017 11:19pm EDT 

Aug 2 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says peptide vaccine related agreement with.  Full Article

OncoTherapy Science says business and capital alliance with Theragen Etex
Wednesday, 12 Jul 2017 01:40am EDT 

July 12 (Reuters) - OncoTherapy Science Inc <4564.T>:* Says it will establish a wholly owened subsidary on July 24.* Say it will transfer research and development of cancer immunotherapy related business to the subsidiary, effective Nov. 1 .* The subsidary will issue 150 new shares to Theragen Etex Co., Ltd. <066700.KQ>, at the price of 1 million yen per share, or 150 million yen in total, and payment date on Aug. 7 .* Theragen Etex Co., Ltd. will acquire 310 shares of the subsidiary, at the price of 1 million yen, for 310 million yen in total, from the co, effective Nov. 15 .* Say the co and Theragen Etex Co., Ltd. Will hold a 64 percent stake and a 36 percent stake finally .  Full Article

OncoTherapy Science announces change of president
Sunday, 26 Feb 2017 09:57pm EST 

OncoTherapy Science Inc <4564.T> : Says co appoints Kazuo Yamamoto as new president, replacing Masaharu Mori who resigns .Change will be effective on Feb. 27.  Full Article

OncoTherapy Science says first-patient enrollment in Phase I/II clinical study of OTS167
Friday, 15 Jul 2016 03:33am EDT 

OncoTherapy Science Inc <4564.T>:Says the first patient has been enrolled in Phase I/II clinical study of OTS167, an MELK-specific inhibitor, for Acute Myeloid Leukemia.  Full Article

OncoTherapy Science gets patent license
Monday, 16 May 2016 04:38am EDT 

OncoTherapy Science Inc <4564.T>: Says received a patent license in China .Says the patent is for specific inhibitor of TOPK (T-LAK cell-originated protein kinase), which being developed as an anti-cancer agent.  Full Article

OncoTherapy Science announces trial result of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma
Tuesday, 22 Mar 2016 07:30pm EDT 

OncoTherapy Science Inc:Announces the positive results of the primary objectives which were safety and bio-distribution were confirmed from Phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’ against synovial sarcoma conducted in France.  Full Article

OncoTherapy Science announces positive trial result of phase I/II clinical study of OTSGC-A24
Monday, 21 Mar 2016 10:30pm EDT 

OncoTherapy Science Inc:Announces positive trial result of phase I/II clinical study of carcinoma peptide vaccine cocktail OTSGC-A24 for the treatment of gastric cancer, in Singapore, Korea and Japan.  Full Article

OncoTherapy Science announces positive trial result of phase I clinical study of MELK inhibitor OTS167
Wednesday, 16 Mar 2016 07:30pm EDT 

OncoTherapy Science Inc:Announces positive trial result of phase I clinical study of MELK inhibitor OTS167 in Australia.Says the clinical study turns out good oral absorption properties of OTS167.  Full Article

OncoTherapy Science announces completion of phase I clinical study of the anti-cancer therapeutic antibody ‘OTSA101’
Sunday, 21 Feb 2016 06:30pm EST 

OncoTherapy Science Inc:Says the phase I clinical study of the anti-cancer therapeutic antibody against synovial sarcoma ‘OTSA101’ has been completed.  Full Article

OncoTherapy Science to start Phase I/II clinical study of OTS167 in USA
Monday, 25 Jan 2016 09:30pm EST 

OncoTherapy Science Inc:Announces commencement of Phase I/II clinical study of OTS167, a MELK specific inhibitor, for Acute Myeloid Leukemia (AML) patients following the approval of the investigational new drug (IND) application by the US Food and Drug Administration (FDA).  Full Article

BRIEF-OncoTherapy Science receives patent in Japan

* Says it received a patent (No.6159948 )for MELK specific inhibitors in Japan